Skip to content
ADVANZ PHARMA logo — Partner of choice in specialty, hospital, and rare disease m...

ADVANZ PHARMA

Partner of choice in specialty, hospital, and rare disease medicines

Founded 1963 United Kingdom London, United Kingdom 734 employees Post-IPO Equity Total: $72.66M Health Care, Pharmaceutical

General Information

Company Name ADVANZ PHARMA
Founded Year 1963
Location United Kingdom London, United Kingdom
Founders / Decision Makers
Team member Team member Team member
Employees 734
Industries Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Business Model B2B, B2B2C
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with ADVANZ PHARMA. To contact ADVANZ PHARMA, visit advanzpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ADVANZ PHARMA compare?

A PDF of ADVANZ PHARMA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ADVANZ PHARMA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ADVANZ PHARMA

ADVANZ PHARMA positions itself as a leading global pharmaceutical firm focused on specialty, hospital, and rare disease medicines, serving a critical role in patient care by providing essential treatments worldwide. Established in 1963 and headquartered in the United Kingdom, the company offers a diverse product mix, including innovative medicines, specialty generics, biosimilars, and originator brands across numerous therapeutic areas such as hepatology, gastroenterology, and rare diseases.

The company's strategic operations span over 90 countries, underpinned by a direct commercial presence in more than 20 key markets, including Europe, the US, Canada, and Australia. They leverage an extensive network supported by a Centre of Excellence in Mumbai, India and strong global distribution partnerships.

Recently, ADVANZ PHARMA attracted investment from Nordic Capital and the Ontario Teachers' Pension Plan in a Post-IPO Equity round dated 26 February 2024, solidifying confidence in its growth trajectory and commercial collaboration capabilities.

Business keywords: specialty medicines, hospital medicines, rare disease medicines, biopharma partnerships, global pharmaceutical company, commercialisation partner, therapeutic areas, innovative medicines, specialty generics, biosimilars, orphan drugs, oncology, gastroenterology, endocrinology, CNS treatments

Services & Products

Commercialization of specialty and rare disease medicines
Pharmaceutical development partnerships
Global distribution of medicines
Biosimilar portfolio development

Target Customers

Biopharma companies Healthcare professionals Hospitals Healthcare systems

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed 2
Nordic Capital, Ontario Teachers' Pension Plan
26 Feb 2024
Post IPO Equity $67.60M 4
Canaccord Genuity Group, GMP Securities +2
11 Mar 2014
Post IPO Equity $5.06M -
28 Dec 2013

ADVANZ PHARMA Alternatives & Competitors

View All Alternatives
ADVANZ PHARMA vs

A Sustainable Platform for Specialty Pharma.

Post-IPO Debt
518 employees
Health Care, Health and Wellness
ADVANZ PHARMA vs

Boosting access to therapeutic advances through entrepreneurial agility

21 employees
Biotechnology, Health Care
ADVANZ PHARMA vs

Your strategic partner in advancing patient health

Private Equity
81 employees
Biotechnology, Health Care

FAQ About ADVANZ PHARMA

Partner of choice in specialty, hospital, and rare disease medicines
ADVANZ PHARMA was founded in 1963.
ADVANZ PHARMA is headquartered in London, United Kingdom.
ADVANZ PHARMA operates in Health Care and Pharmaceutical. Its work centres on specialty medicines, hospital medicines, rare disease medicines and biopharma partnerships. Its customers include Biopharma companies, Healthcare professionals and Hospitals.
ADVANZ PHARMA has a B2B and B2B2C business model. Its revenue comes from Product Sales, Licensing and Service Fee.
ADVANZ PHARMA has approximately 734 employees.
ADVANZ PHARMA has completed 3 funding rounds, raising a total of $72.66M. The latest funding stage is Post-IPO Equity.
ADVANZ PHARMA offers: Commercialization of specialty and rare disease medicines, Pharmaceutical development partnerships, Global distribution of medicines, Biosimilar portfolio development.
Top alternatives and competitors to ADVANZ PHARMA include CHEPLAPHARM, iQone Healthcare Switzerland, TMC Pharma Services Ltd, GL Pharma UK, Daiichi Sankyo Japan. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ADVANZ PHARMA and CHEPLAPHARM are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ADVANZ PHARMA, https://bouncewatch.com/company/advanz-pharma, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout